CAJ | 학술논문

目的：研究益生菌对肠易激综合征(irritable bowel syndrome，IBS)合并小肠细菌过度生长(small intestinal bacterial overgrowth，SIBO)的治疗效果。方法选择2012年1月-2013年8月我院诊断的 IBS 患者100例为研究对象，男性38例，女性62例，年龄(44.7±8.1)岁。所有患者均完成甲烷-氢呼气试验，将64例阳性者随机分为抗生素组(22例，利福昔明治疗)、微生态组(21例，双岐杆菌三联活菌胶囊治疗)及安慰剂组(21例，安慰剂治疗)，比较3组患者治疗前后临床症状积分、小肠细菌过度生长转阴率、治疗有效率之间的差异。结果抗生素组(11.39±3.67 vs 4.96±1.19)与微生态组(11.38±3.46 vs 4.89±1.17)治疗前后的临床症状积分均明显改善(P ＜0.001)；微生态组治疗后临床症状积分(4.89±1.17)、总有效率(85.71%)及 SIBO 转阴率(71.43%)与抗生素组(4.96±1.19，86.36%，72.73%)差异无统计学意义(P ＞0.05)；抗生素组、微生态组治疗后临床症状积分、总有效率及转阴率与安慰剂组治疗后(10.23±3.43，28.57%，9.50%)差异均有统计学意义(P ＜0.05)。结论双歧杆菌三联活菌胶囊与利福昔明疗效同样确切，微生态制剂可以广泛用于 IBS 合并 SIBO 的治疗。
목적：연구익생균대장역격종합정(irritable bowel syndrome，IBS)합병소장세균과도생장(small intestinal bacterial overgrowth，SIBO)적치료효과。방법선택2012년1월-2013년8월아원진단적 IBS 환자100례위연구대상，남성38례，녀성62례，년령(44.7±8.1)세。소유환자균완성갑완-경호기시험，장64례양성자수궤분위항생소조(22례，리복석명치료)、미생태조(21례，쌍기간균삼련활균효낭치료)급안위제조(21례，안위제치료)，비교3조환자치료전후림상증상적분、소장세균과도생장전음솔、치료유효솔지간적차이。결과항생소조(11.39±3.67 vs 4.96±1.19)여미생태조(11.38±3.46 vs 4.89±1.17)치료전후적림상증상적분균명현개선(P ＜0.001)；미생태조치료후림상증상적분(4.89±1.17)、총유효솔(85.71%)급 SIBO 전음솔(71.43%)여항생소조(4.96±1.19，86.36%，72.73%)차이무통계학의의(P ＞0.05)；항생소조、미생태조치료후림상증상적분、총유효솔급전음솔여안위제조치료후(10.23±3.43，28.57%，9.50%)차이균유통계학의의(P ＜0.05)。결론쌍기간균삼련활균효낭여리복석명료효동양학절，미생태제제가이엄범용우 IBS 합병 SIBO 적치료。
Objective To observe the clinical effect of probiotics on irritable bowel syndrome (IBS) with small intestinal bacterial overgrowth (SIBO) and provide basis for the application of probiotics in IBS treatment. Methods From January 2012 to August 2013, 100 IBS patients (38 males and 62 females with an average age of 44.7±8.1 years) were chosen as research object in our hospital. According to the result of methane-hydrogen breath test, 64 SIBO patients were divided into 3 groups randomly (antibiotics group, probiotics group and placebo group) and received treatment with rifaximin, Bifidobacterium triple viable capsules and placebo separately. After treatment, the difference of their clinical symptom score, SIBO negative rate and treatment efficiency were compared. Results Compared with the integral before treatment, the clinical symptom integral of antibiotics group (11.39±3.67 vs 4.96±1.19) and probiotics group (11.38±3.46 vs 4.89±1.17) decreased significantly, their difference had statistical significance (P <0.001). Compared with antibiotics group (4.96±1.19, 86.36%, 72.73%), the clinical symptom integral (4.89±1.17), treatment efficiency (85.71%) and negative rate (71.43%) in probiotics group had no statistical significance (P > 0.05). Compared with placebo group (10.23±3.43, 28.57%, 9.50%), the clinical symptom integral, treatment efficiency and negative rate of antibiotics group and probiotics group had statistical significance (P < 0.05). Conclusion Bifidobacterium triple viable capsules has the same clinical effect with rifaximin. Probiotics can be widely used in the treatment of IBS with SIBO.